Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-18)

In this article we will discuss Durvalumab (Warnings-18)

In this article, we will discuss Durvalumab (Warnings-18). So, let’s get started.

Grade 3 hypophysitis/hypopituitarism occurred in <0.1% (1/1889) of patients who received Durvalumab. Treatment with systemic corticosteroids was administered in this patient. The event did not lead to permanent discontinuation of Durvalumab.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.